(19)
(11) EP 4 512 402 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
30.04.2025 Bulletin 2025/18

(43) Date of publication A2:
26.02.2025 Bulletin 2025/09

(21) Application number: 25150164.9

(22) Date of filing: 18.08.2022
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 3/00(2006.01)
A61P 35/00(2006.01)
 C07D 519/00(2006.01)
A61P 29/02(2006.01)
A61K 31/498(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 471/04; C07D 519/00; A61P 35/00; A61P 3/00; A61P 29/02; Y02A 50/30
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.08.2021 US 202163234606 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
22785813.1 / 4367118

(71) Applicants:
  • Nurix Therapeutics, Inc.
    San Francisco, CA 94158 (US)
  • Gilead Sciences, Inc.
    Foster City, CA 94404 (US)

(72) Inventors:
  • PALMER, Wylie
    San Francisco, 94158 (US)
  • WU, Jeffrey
    San Francisco, 94158 (US)
  • LEE, John
    San Francisco, 94158 (US)
  • OZBOYA, Kerem
    San Francisco, 94158 (US)
  • KANE, Tim
    San Francisco, 94158 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF


(57) The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.





Search report









Search report